News
News
Academy
Multimedia
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conferences
Conference CoverageConference Listing
More
Publications
Pharmaceutical Executive
Partner Perspectives
Resources
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers

Subscribe

  • News
  • Academy
  • Multimedia
  • Conferences
  • Publications
  • Partner Perspectives
  • Resources
  • Subscribe
  • Corporate Communications
    • Press Releases
    • Executive Roundtable
    • Executive Profiles
    • Leadership
  • Direct-to-Consumer
    • Patient Education
    • Healthcare Access
    • Telehealth
  • Emerging Biopharma
    • Partnerships
    • Funding
  • IR Licensing and Partnerships
    • Finance
    • Industry Trends
  • Market Access
    • Patient Access
    • Pricing
    • Strategy
  • Medical Affairs
    • Patient Advocacy
    • Clinical Data
    • Pharmacovigilance
  • Operations
    • Sustainability
    • Technology
    • R&D/Clinical Trials
    • Supply Chain
  • Patient Engagement
    • DE&I
  • Regulatory
    • FDA
    • Legal
    • Global
  • Sales & Marketing
    • Sales Effectiveness
    • Campaigns
    • DTC Marketing
    • Medical Education
Spotlight -
Latest Executive Roundtables|
Asembia 2025 |
Sales Effectiveness
Advertisement
|Articles|October 23, 2018

The Future of JAK Inhibitors Figure 1

Author(s)Denise Baldock, Elizabeth Baynton, Amanda Baskett, and Nicola Bailey
Advertisement
External Link - Future-of-JAKs_Figure 1.pdf

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Advertisement

Related Content

Advertisement

To Build or to Buy: Determining Your AI Path

ByRathi Suresh, PhD
January 20th 2026
Angela Schwab

How Are Sites Impacted by Poor Planning and Trial Design?

ByMike Hollan,Angela Schwab
January 13th 2026
Angela Schwab

How Can Teams Reduce Patient Burden Without Weakening Their Science?

ByMike Hollan,Angela Schwab
January 12th 2026
Angela Schwab

Can AI Help Solve the Issue of High Failure Rates in Clinical Trials?

ByMike Hollan,Angela Schwab
January 9th 2026
Image Credit: Adobe Stock Images/KRISTINA KUPTSEVICH

Lilly’s Orforglipron, Retatrutide Named as Defining GLP-1 Drugs of the Next Decade

ByDavy James
January 8th 2026
Advertisement
Advertisement

Trending on PharmExec

1

Pharmaceutical Executive Daily: Tariff Uncertainty Accelerates Manufacturing Shifts

2

Tariff Uncertainty Drives Short-Term Manufacturing Surge as Global Pharmaceuticals Enter Fragmented Growth Phase: Report

3

Burnout and Shortages Put the Blood Supply at Risk

4

WHO Finalizes United States’ Withdrawal from Organization: Report

5

What is Daiichi Sankyo’s Post JP Morgan Strategy?

  • About
  • Advertise
  • Contact Us
  • Editorial Board
  • Editorial Submission Guidelines
  • Do Not Sell My Personal Information
  • Privacy Policy
  • Terms and Conditions
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us